BPTH

-- -- --

From December 31, 2023 to March 31, 2024 Issuance of common stock, net of fees

Common stock offered 75,000 shares by the company

Bio-Path Holdings, Inc. announced that it intends to effect a reverse stock split of its outstanding common stock, par value $0.001 per share, at a ratio of 1-for-20. The reverse stock split will be effective as of 5:30 p.m., Eastern Time on February 22, 2024, and the Company’s common stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market at the commencement of trading on February 23, 2024.

From June 30, 2023 to September 30, 2023 Issuance of common stock, net of fees

Common stock offered 3,500,000 shares by the company

From December 31, 2021 to December 31, 2022 Issuance of common stock, net of fees

From June 30, 2021 to September 30, 2021 Issuance of common stock, net of fees

From December 31, 2020 to March 31, 2021 Issuance of common stock, net of fees Exercise of warrants, net of fees

1.Common stock offered by the company 1,710,600 shares. 2.The number of shares of common stock to be outstanding after this offering is based on 5,237,312 shares of common stock outstanding as of the date of this prospectus supplement.

From December 31, 2019 to December 31, 2020 Issuance of common stock, net of fees

from December 31, 2018 to December 31, 2019 Issuance of common stock, net of fees Exercise of warrants, net of fees

From June 30, 2019 to September 30, 2019 Exercise of warrants, net of fees

from March 31, 2019 to June 30, 2019 Exercise of warrants, net of fees

from December 31, 2018 to March 31, 2019 Issuance of common stock, net of fees Exercise of warrants, net of fees

On January 17, 2019, the Company effected a reverse stock split of our outstanding shares of common stock at a ratio of 1-for-20, and our common stock began trading on the split-adjusted basis on The Nasdaq Capital Market at the commencement of trading on January 18, 2019

1.Bio-Path Holdings, Inc., (Nasdaq: BPTH) (Bio-Path), a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the pricing of an underwritten public offering of 8,592,308 shares of its common stock at a price to the public of $0.13 per share. Bio-Path expects to receive aggregate gross proceeds of approximately $1.1 million from the offering. The offering is expected to close on or about January 17, 2019, subject to the satisfaction of customary closing conditions. 2.At the 2018 Annual Meeting of Stockholders of Bio-Path Holdings, Inc. (the “Company”) held on December 20, 2018, the Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s common stock, par value $0.001 per share, at a ratio of up to 1-for-20, to be determined by the Company’s board of directors, subject to the authority of the board of directors to abandon such reverse stock split in its discretion. On January 11, 2019, the board of directors approved a ratio for the reverse stock split of 1-for-20.

Bio-Path Holdings, Inc. announces a 1-for-10 reverse stock split of its issued and outstanding common stock.The reverse stock split became effective at 5:00 pm Eastern Time on February 8, 2018, and the Company's shares of common stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market at the commencement of trading on February 9, 2018.The reverse stock split reduced the Company's issued and outstanding shares of common stock from approximately 113.4 million to approximately 11.3 million.

from December 31, 2015 to September 30, 2016 Issuance of common stock, net of fees

from December 31, 2013 to December 31, 2014 Common stock sold to institutional investor Exercise of stock options

From December 31,2012 to December 2,2013 Common stock issued to Placement Agent Shares issued for common stock previously sold